Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data
Open accessThe DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index.
Abstract
Background: Recent evidence has emerged concerning hypoglycemia following the application of glucagon-like peptide-1 receptor agonists (GLP-1RAs). Nevertheless, few real-world investigations have been performed to determine the clinical characteristics, onset, and outcomes of hypoglycemia associated with different GLP-1RAs. This study aimed to compare and assess the relationship between various GLP-1RAs and hypoglycemia in a large population based on updated data from the Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: Bayesian and disproportionality analyses were applied to data mining in order to investigate suspected cases of hypoglycemia following various GLP-1RAs using the FAERS data between January 2004 and September 2020. We also evaluated the onset time, fatality risks, and hospitalization proportions of GLP-1RA-related hypoglycemia. Results: We identified 1,164 GLP-1RA-associated hypoglycemia cases, which seemed to affect more middle-aged patients than elderly ones. Also, females were more affected than males. Lixisenatide demonstrated a stronger association with hypoglycemia compared to other GLP-1RAs, according to the highest reporting odds ratio (ROR) (28.03, 95% confidence interval =15.92, 49.32), empirical Bayes geometric mean [26.00, 95% confidence interval (CI): 16.20], and proportional reporting ratio (PRR) (26.01, χ2=313.37). The median time to hypoglycemia onset was 5 days (interquartile range, 0–67.75 days) following GLP-1RA treatment. In general, GLP-1RA-associated hypoglycemia resulted in fatality and hospitalization proportions of 3.53% and 56.08%, respectively. Conclusions: By analyzing the FAERS data, we outlined the association between hypoglycemia and different GLP-1RAs in greater detail in terms of clinical features, onset, and outcomes. Among all six GLP-1RAs, lixisenatide demonstrated the strongest association with hypoglycemia while no relationship between albiglutide and hypoglycemia was observed. Attention should be given to GLP-1RAs when used in patients with high risks of hypoglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which might be due to the high incidence of diabetes in patients aged 18–65 years (27).”
From Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system (2022) · cites this paper as [27]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297 · cited 1×
“might be due to the fact that the majority of diabetes patients were aged 45–64 years (33).”
BackgroundLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“In addition to the outstanding glucoselowering effects on patients with type 2 diabetes, GLP-1RAs have also shown benefits in several cardiovascular outcome trials, including LEADER (4), SUSTAIN 6 (5), Harmony Outcomes (6), and REWIND (7).”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“In addition to the outstanding glucoselowering effects on patients with type 2 diabetes, GLP-1RAs have also shown benefits in several cardiovascular outcome trials, including LEADER (4), SUSTAIN 6 (5), Harmony Outcomes (6), and REWIND (7).”
BackgroundDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · cited 2×
“Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebocontrolled trial.”
BackgroundDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030
Rathmann, W., & Giani, G. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2568 · Cited by 1,994
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829 · cited 2×
“Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.”
BackgroundGlobal Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030
Wild, S. H., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2569-a · Cited by 1,477
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · cited 1×
“In an early clinical trial, exenatide combined with sulphonylureas resulted in an elevated incidence of mild-to-moderate hypoglycemia (27).”
BackgroundGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 2×
“These drugs can be classified into two groups, long-acting (dulaglutide, albiglutide, semaglutide, liraglutide, and once-weekly exenatide) and short-acting (lixisenatide and twice-daily exenatide) regimens, based on the duration of action (1).”
BackgroundBuse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Data Mining of the Public Version of the FDA Adverse Event Reporting System
Sakaeda, T., Tamon, A., Kadoyama, K., & Okuno, Y. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.6048 · Cited by 1,048
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835 · cited 1×
“Moreover, hypoglycemia was reported as an adverse event related to liraglutide both in primary clinical trials and post-marketing surveillance (15,29,30).”
Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 820
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560 · cited 1×
“Despite their beneficial effects, some adverse events are reportedly associated with GLP-1RAs (10).”
BackgroundManagement of Hyperglycemia in Type 2 Diabetes
SKOLNIK, N., & OLSON, C. (2012) · Family Practice News · doi:10.1016/s0300-7073(12)70593-5 · Cited by 519
Montastruc, J., Sommet, A., Bagheri, H., & Lapeyre‐Mestre, M. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04037.x · Cited by 517
Singh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467 · cited 1×
“Also, it is concerning that the use of GLP-1RAs may be related to an elevated risk of acute pancreatitis, and the FDA has warned the public about this adverse event associated with exenatide usage (12).”
BackgroundNauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429 · cited 1×
“Although GLP-1RAs are often thought to be linked to a relatively lower risk of hypoglycemia (13), the combination of GLP-1RAs and other anti-diabetic medications (e.”
BackgroundHtike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12849 · Cited by 416 · cited 3×
“Nevertheless, no difference of hypoglycemia risks among all the GLP-1RAs was revealed by the review, indicating no difference of hypoglycemia rate exists between long-acting and short-acting (3).”
BackgroundResultInfluentialEng, C., Kramer, C. K., Zinman, B., & Retnakaran, R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61335-0 · Cited by 383
Seino, Y., Min, K. W., Niemoeller, E., Takami, A., & on behalf of the EFC10887 GETGOAL‐L Asia Study Investigators (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01618.x · Cited by 255 · cited 1×
“Although accumulating studies report the occurrence of hypoglycemia following the use of GLP-1RAs in patients with type 2 diabetes, most evidence comes from clinical trials (18,19), which is insufficient to systematically understand the risk or characteristics of such a relatively rare adverse event.”
BackgroundInfluentialGlucagon-like peptide analogues for type 2 diabetes mellitus
Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006423.pub2 · Cited by 246 · cited 1×
“, sulphonylureas) have shown an elevated risk of hypoglycemia compared to placebo (14).”
BackgroundSun, F., Chai, S., Yu, K., Quan, X., Yang, Z., Wu, S., Zhang, Y., Ji, L., Wang, J., & Shi, L. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0188 · Cited by 158 · cited 1×
“The most frequently occurring events are gastrointestinal disorders, such as nausea, diarrhea, vomiting, abdominal pain, and so on (11).”
BackgroundSemaglutide for type 2 diabetes mellitus: A systematic review and meta‐analysis
Andreadis, P., Karagiannis, T., Malandris, K., Avgerinos, I., Liakos, A., Manolopoulos, A., Bekiari, E., Matthews, D. R., & Tsapas, A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13361 · Cited by 153 · cited 1×
“In addition, hypoglycemia was also present in patients treated with other GLP-1RAs, like lixisenatide (16), albiglutide (17), dulaglutide (31), and semaglutide (32).”
BackgroundBayesian Confidence Propagation Neural Network
Bate, A. (2007) · Drug Safety · doi:10.2165/00002018-200730070-00011 · Cited by 149
Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents
Gallwitz, B. (2011) · Drugs · doi:10.2165/11592810-000000000-00000 · Cited by 142
Rosenstock, J., Hanefeld, M., Shamanna, P., Min, K. W., Boka, G., Miossec, P., Zhou, T., Muehlen-Bartmer, I., & Ratner, R. E. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.01.012 · Cited by 130 · cited 2×
“In addition, hypoglycemia was also present in patients treated with other GLP-1RAs, like lixisenatide (16), albiglutide (17), dulaglutide (31), and semaglutide (32).”
BackgroundHome, P. D., Shamanna, P., Stewart, M., Yang, F., Miller, M., Perry, C., & Carr, M. C. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12414 · Cited by 101
Comparison of data mining methodologies using Japanese spontaneous reports
Kubota, K., Koide, D., & Hirai, T. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.964 · Cited by 91 · cited 1×
“To identify novel signals for specific adverse events from accumulating spontaneous reports collected by pharmacovigilance systems, data mining methods have been widely used, including disproportionality assessment and Bayesian analysis (22,23).”
MethodSelected control events and reporting odds ratio in signal detection methodology
Ooba, N., & Kubota, K. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2014 · Cited by 75 · cited 1×
“The disproportionality methodologies using proportional reporting ratio (PRR) and reporting odds ratio (ROR) were employed in our study (24,25).”
MethodIqbal, A., & Heller, S. R. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.004 · Cited by 64
Chan, S.-P., Ji, L.-N., Nitiyanant, W., Baik, S. H., & Sheu, W. H. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.05.008 · Cited by 44
Mali, G., Ahuja, V., & Dubey, K. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13259 · Cited by 44 · cited 1×
“Currently, limited pharmacovigilance studies about GLP-1RAs have mainly focused on other related adverse events (20,21), and little is known about the explicit features of hypoglycemia following the application of different GLP-1RAs in real-world practice.”
BackgroundZhang, L., Zhang, M., Zhang, Y., & Tong, N. (2016) · Scientific Reports · doi:10.1038/srep18904 · Cited by 43 · cited 1×
“In addition, hypoglycemia was also present in patients treated with other GLP-1RAs, like lixisenatide (16), albiglutide (17), dulaglutide (31), and semaglutide (32).”
BackgroundPradhan, R., Montastruc, F., Rousseau, V., Patorno, E., & Azoulay, L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30382-1 · Cited by 32 · cited 1×
“Currently, limited pharmacovigilance studies about GLP-1RAs have mainly focused on other related adverse events (20,21), and little is known about the explicit features of hypoglycemia following the application of different GLP-1RAs in real-world practice.”
BackgroundIntentional overdose of liraglutide in a non-diabetic patient causing severe hypoglycemia
Solverson, K., Lee, H., & Doig, C. J. (2018) · Canadian Journal of Emergency Medicine · doi:10.1017/cem.2017.439 · Cited by 27 · cited 1×
“Moreover, a recent case report about hypoglycemia showed that a female diabetes patient had not recovered from liraglutide-related hypoglycemia until she received dextrose infusion, which suggests that dextrose supplementation is important if hypoglycemia persists (38).”
BackgroundGosho, M. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1147 · Cited by 20 · cited 1×
“In a study analyzing the risk of hypoglycemia after glucose-lowering treatment utilizing the Japanese Adverse Drug Event Report (JADER) database, lixisenatide also showed higher ROR and IC values than the other two GLP-1RAs, exenatide and liraglutide (35).”
An accidental liraglutide overdose: case report
Elmehdawi, R. R., & Elbarsha, A. M. (2014) · Libyan Journal of Medicine · doi:10.3402/ljm.v9.23055 · Cited by 16 · cited 1×
“According to a case of hypoglycemia associated with liraglutide use, supportive measures can also be taken to alleviate symptoms (37).”
BackgroundPencek, R., Brunell, S. C., Li, Y., Hoogwerf, B. J., & Malone, J. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2568 · Cited by 15 · cited 2×
“Although accumulating studies report the occurrence of hypoglycemia following the use of GLP-1RAs in patients with type 2 diabetes, most evidence comes from clinical trials (18,19), which is insufficient to systematically understand the risk or characteristics of such a relatively rare adverse event.”
BackgroundInfluentialMartinez, L., Penfornis, A., Gautier, J., Eschwège, É., Charpentier, G., Bouzidi, A., & Gourdy, P. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0476-0 · Cited by 12 · cited 1×
“Moreover, hypoglycemia was reported as an adverse event related to liraglutide both in primary clinical trials and post-marketing surveillance (15,29,30).”
BackgroundHwang, Y., Kim, A., Jo, E., Yang, Y., Cho, J., & Lee, B. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0220-4 · Cited by 6 · cited 1×
“72% of enrolled patients treated with exenatide in addition to original anti-diabetic therapies (28).”
Background
Cited by
Shu, Y., He, X., Wu, P., Liu, Y., Ding, Y., & Zhang, Q. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.996179 · Cited by 145
Ghusn, W., & Hurtado, M. D. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100127 · Cited by 122
“However, hypoglycemia remains a possible risk that should be taken into account when prescribing this medication in patients treated with insulin secretagogues or insulin, as shown in previous studies [32].”
ResultGLP-1 receptor agonist as a modulator of innate immunity
Chen, J., Mei, A., Wei, Y., Li, C., Qian, H., Min, X., Yang, H., Dong, L., Rao, X., & Zhong, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997578 · Cited by 120
“Glucagon-like peptide-1 (GLP-1) is an endogenous incretin secreted by small intestinal L cells, consisting of two bioactive isoforms: GLP-1 (7-37) and GLP-1 (736).”
BackgroundWeight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“Headaches, dizziness, hypoglycemia, and injection site reactions have also been reported albeit to a much lesser degree [188,189].”
Jalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., Umapathysivam, M. M., Wu, T., Quast, D. R., Plummer, M. P., Nauck, M. A., & Horowitz, M. (2024) · Endocrinology · doi:10.1210/endocr/bqae155 · Cited by 61
Metadata
- Authors
- Zhao, Z., Tang, Y., Hu, Y., Zhu, H., Chen, X., & Zhao, B.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Zhao, Bin
- Venue
- Annals of Translational Medicine
- Publisher
- AME Publishing Company
- Published
- 2021-09
- Volume
- 9
- Issue
- 18
- Pages
- 1482-1482
- ISSN
- 2305-5839 (ISSN-L)
- 2305-5847
- PMC
- PMC8506728
- OpenAlex
- W3201672265
- Cited by
- 49
- References
- 45
- Citations by year
- 2026: 16 · 2025: 14 · 2024: 10 · 2023: 5 · 2022: 3 · 2021: 1
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Annals of Translational Medicine (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- receptor agonists, hypoglycemia, drug safety, lixisenatide, albiglutide, saxagliptin, liraglutide, dulaglutide, tirzepatide, adverse drug reactions, post-marketing surveillance, FDA Adverse Event Reporting System, disproportionality analysis, Bayesian analysis, time to onset, hospitalization, mortality, type 2 diabetes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.